Brief by Shorts91 Newsdesk / 06:46pm on 01 Jun 2026,Monday Health & Wellness
A large international study has found that many breast cancer patients can safely avoid chemotherapy with the help of a gene test called Prosigna. The OPTIMA trial followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Researchers found that patients aged 40 and above with hormone-sensitive breast cancer and a low Prosigna score had similar outcomes whether they received chemotherapy or only hormone therapy. After five years, 94.8% of patients who received chemotherapy and hormone therapy were cancer-free, compared with 93.6% of those treated with hormone therapy alone. Experts said the findings could change treatment practices and help over 5,000 NHS patients each year avoid unnecessary chemotherapy and its side effects. The results will be presented at the ASCO 2026 meeting. (PC: AI Generated)
